Warning: ftp_fget() expects parameter 1 to be resource, null given in /kunden/544968_30625/webseiten/vpm-2022/prime-vaccine/wp-admin/includes/class-wp-filesystem-ftpext.php on line 146
Home -

#priMe infants to stop
TB

Tuberculosis (TB) is one of the top 10 causes of death worldwide. An estimated 10 million people fell ill with TB in 2020 with approximately 1.4 million dying from the disease. In children, BCG vaccination can protect against, or at least ameliorate, severe forms of systemic TB, particularly TB meningitis. Ultimately, to interrupt transmission of the disease, highly contagious pulmonary forms of TB also need to be targeted by vaccination. The priMe project evaluates the efficacy and safety of a new vaccine candidate against TB.

About priMe

In 1993, the World Health Organization (WHO) declared tuberculosis (TB) a global emergency. Approx. 2 billion people are infected and 10 million people are estimated to have fallen ill with TB in 2019. In the same year approx. 1.4 million died because of TB. South Africa and other Sub-Saharan countries belong to the group of “high-burden” TB countries with an estimated total incidence of 360,000 TB cases in 2019 in South Africa alone.

In children BCG can protect against, or at least ameliorate, severe forms of systemic TB, particularly TB meningitis.

VPM1002 is an innovative live vaccine against TB, based on the well-known Mycobacterium bovis (M. bovis) Bacille Calmette-Guérin (BCG) strain which has been administered approximately 4 billion times worldwide.

The genetic modifications of VPM1002, namely introduction of listeriolysin while simultaneously deleting the gene for urease C in the BCG genome, are aiming for better recognition by the host immune system.

News and Press

Wrapping Up priMe’s Annual Meeting: A Journey Towards Success

30.11.2023 Wrapping Up priMe’s Annual Meeting: A Journey Towards Success With a round of applause and a plethora of insights, Day 2 marks the exciting conclusion of our priMe trial meeting in Entebbe, Uganda. Highlights of Day Two: Collective Progress: Each discussion, achievement, and partnership today propelled us closer to our goal of trial success—a testament to our collective progress. Acknowledging Contributions: Reco…

First Day Insights from the priMe Annual Meeting

29.11.2023 First Day Insights from the priMe Annual Meeting The first day at the annual meeting of the pivotal priMe trial held in Entebbe, Uganda, was marked by significant discussions and achievements. Key Takeaways from Day One: Strategic Collaboration: We began by highlighting the power of collaboration in developing forward the VPM1002 vaccine developed against Tuberculosis and its impact on global healthcare. Strong part…
Scroll to Top